Navigation Links
Inscent, Inc. Receives Federal Grant to Develop Honeybee Repellents
Date:4/28/2008

IRVINE, Calif., April 28 /PRNewswire/ -- Inscent, Inc. has received a Small Business Innovative Research grant from the US National Science Foundation (NSF) to continue the testing and development of novel honeybee repellents using the proprietary Attenu high throughput assay system. The pioneering research performed by Inscent, Inc. has resulted in highly efficient processes that allow the rapid development of revolutionary insect control products suited for the modern age. Inscent's groundbreaking paradigm shift away from traditional insecticides and toward products based on behavior alteration of targeted species has been supported extensively by federal research grants and private industry funds. NSF reviewers described the honeybee repellent project as "fascinating" and "highly desirable," and new federal funding commences in July 2008.

Inscent, Inc. is designing environmentally responsible insect control products that will eclipse the current generation of insecticides. The company's latest efforts focus on the honeybee, Apis mellifera, an economically and agriculturally crucial insect species, for the development of a new array of insect control products based on behavior alteration. Inscent's honeybee repellent project was originally funded by the Citrus Research Board (CRB; http://www.citrusresearch.org), a coalition of California growers at the global forefront of citrus industry-funded scientific research.

The honeybee, Apis mellifera, is critical to US agriculture, and a Cornell University study estimated the direct value of honeybee pollination in this country exceeds $14 billion annually. Although the initial use of the repellent will be to prevent seediness in mandarins, it will also provide a solution for keeping bees out of fields that have been treated with insecticides. Honeybees are threatened by insecticide use and recent incidents of colony collapse have caused great concern among the farming and apiculture industries. These factors have combined to generate an urgent need for effective products that are safe to humans and insects alike.

Inscent, Inc. has developed a number of novel platform technologies to exploit the wide variety, selectivity, and high sensitivity of insect chemosensory systems. This proprietary collection of chemosensory proteins is being used to develop a series of non-toxic, highly efficient insect pest control products. Inscent's new technologies are applicable to a wide array of insect pest species that impact the agricultural, domestic, and public health sectors. Inscent's platform technologies utilize the latest developments in molecular genetics, genomics, and bioinformatics to design advanced, environmentally responsible insect pest control solutions and effective, sensitive biosensors. Further information on Inscent is available on the web at http://www.inscent.com.

The National Science Foundation is an independent federal agency that supports fundamental research and education across all fields of science and engineering. NSF also encourages scientific innovation and discovery in the commercial sector, primarily through the Small Business Innovative Research (SBIR) program. Further information on NSF is available on the web at http://www.nsf.gov.

Inscent, Inc. welcomes inquiries from qualified investors and potential strategic allies.


'/>"/>
SOURCE Inscent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: